Google venture arm backs UK universal flu vaccine company

Vaccitech said the cash would help fund its vaccine through a two-year clinical trial involving more than 2,000 patients and expand other projects

Ben Hirschler
Published15 Jan 2018, 10:35 AM IST
Vaccitech’s new vaccine works by using proteins found in the core of the virus rather than those on its surface. Photo: Reuters
Vaccitech’s new vaccine works by using proteins found in the core of the virus rather than those on its surface. Photo: Reuters

London: A private British company developing a vaccine that would be the first in the world to fight all types of flu has raised 20 million pounds ($27 million) from investors including GV, the venture capital arm of Google parent Alphabet Inc.

Vaccitech, a spin-out founded by scientists at Oxford University’s Jenner Institute, said on Monday the cash would help fund its vaccine through a two-year clinical trial involving more than 2,000 patients and expand other projects.

The group is also running clinical studies on an experimental shot to prevent Middle East Respiratory Syndrome (MERS) and a therapeutic prostate cancer vaccine for use with an immunotherapy drug. Recent advances have made such vaccine-drug combinations a hot area of cancer research.

A so-called universal flu vaccine that elicits immunity against parts of the virus that do not change from year to year is a holy grail of medicine-but so far it has proved elusive.

Current flu vaccines have to be changed each year to match strains of virus circulating at the time. The hope is the new one-size-fits-all vaccine will provide better and longer-lasting protection.

Vaccitech’s new vaccine works by using proteins found in the core of the virus rather than those on its surface. Surface proteins stick out like pins from the virus and change all the time, while those in the core are stable.

It also stimulates T-cells rather than antibodies - an approach that has yet to convince existing flu vaccine manufacturers like Sanofi, GlaxoSmithKline and CSL’s Seqirus.

Still, Vaccitech chief executive Tom Evans is confident the big players will come around if the current mid-stage clinical trial is a success and he will not have a problem in finding a partner to take the product into final-stage Phase III tests.

“If we get positive data that shows we can affect rates of hospitalisation and illness with influenza then there is no question in my mind that a partner would take this on,” he told Reuters. “This could be a game-changer in a very competitive market.”

The Vaccitech trial marks the first time that a universal flu vaccine has progressed beyond Phase I clinical testing.

If all goes well, Vaccitech’s shot could potentially be ready for launch in 2023, although Evans said 2024 or 2025 might be more realistic. That means financial backers need to take a long view, especially as its other programmes using T-cells to make vaccines against cancer, MERS, hepatitis B and human papillomavirus are also at an early stage.

“We wanted people who were willing to stick with us for a while and had bigger pockets for doing secondary rounds,” Evans said.

Vaccitech’s latest financing round was also supported by Sequoia China and Oxford Sciences Innovation. Reuters

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

MoreLess
First Published:15 Jan 2018, 10:35 AM IST
Business NewsScienceHealthGoogle venture arm backs UK universal flu vaccine company

Get Instant Loan up to ₹10 Lakh!

  • Employment Type

    Most Active Stocks

    NTPC share price

    392.45
    03:59 PM | 11 NOV 2024
    -5.25 (-1.32%)

    Tata Motors share price

    804.75
    03:59 PM | 11 NOV 2024
    -0.95 (-0.12%)

    ICICI Bank share price

    1,269.15
    03:58 PM | 11 NOV 2024
    9.8 (0.78%)

    Tata Steel share price

    144.95
    03:42 PM | 11 NOV 2024
    -2.6 (-1.76%)
    More Active Stocks

    Market Snapshot

    • Top Gainers
    • Top Losers
    • 52 Week High

    Wipro share price

    572.25
    03:59 PM | 11 NOV 2024
    3.4 (0.6%)

    Federal Bank share price

    207.75
    03:51 PM | 11 NOV 2024
    1 (0.48%)

    Indian Hotels Company share price

    729.45
    03:59 PM | 11 NOV 2024
    -3.6 (-0.49%)

    Page Industries share price

    47,349.95
    03:29 PM | 11 NOV 2024
    -637.85 (-1.33%)
    More from 52 Week High

    Asian Paints share price

    2,542.65
    03:44 PM | 11 NOV 2024
    -226.6 (-8.18%)

    CE Info Systems share price

    1,890.15
    03:53 PM | 11 NOV 2024
    -165.65 (-8.06%)

    UPL share price

    515.10
    03:47 PM | 11 NOV 2024
    -42.5 (-7.62%)

    Aarti Industries share price

    439.55
    03:58 PM | 11 NOV 2024
    -35.2 (-7.41%)
    More from Top Losers

    Biocon share price

    348.85
    03:58 PM | 11 NOV 2024
    27.6 (8.59%)

    Borosil Renewables share price

    503.10
    03:40 PM | 11 NOV 2024
    37.5 (8.05%)

    ITI share price

    327.40
    03:59 PM | 11 NOV 2024
    23.8 (7.84%)

    Power Finance Corp share price

    481.60
    03:58 PM | 11 NOV 2024
    32.15 (7.15%)
    More from Top Gainers

    Recommended For You

      More Recommendations

      Gold Prices

      • 24K
      • 22K
      Bangalore
      78,775.00-600.00
      Chennai
      78,781.00-600.00
      Delhi
      78,933.00-600.00
      Kolkata
      78,785.00-600.00

      Fuel Price

      • Petrol
      • Diesel
      Bangalore
      102.92/L0.00
      Chennai
      100.80/L0.00
      Kolkata
      104.95/L0.00
      New Delhi
      94.77/L0.00

      Popular in Science

        HomeMarketsPremiumInstant LoanMint Shorts